You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 9,562,223


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,562,223
Title:Methods for reducing intraocular pressure by administering a soluble hyaluronidase glycoprotein (sHASEGP)
Abstract: Provided are methods for reducing intraocular pressure in the eye of a subject by administering neutral active soluble active hyaluronidase glycoproteins (sHASEGPs) and modified forms thereof to the eye. The sHASEGPs are soluble forms of human PH20 hyaluronidase. Also provided are the sHASEGPs, methods of manufacture, and uses thereof. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described. The sHASEGPs include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain.
Inventor(s): Bookbinder; Louis (San Diego, CA), Kundu; Anirban (San Diego, CA), Frost; Gregory I. (Palm Beach, FL)
Assignee: Halozyme, Inc. (San Diego, CA)
Application Number:13/999,454
Patent Claims:1. A method for reducing intraocular pressure in the eye of a subject, comprising administering a composition comprising a hyaluronidase polypeptide to the eye, wherein: the hyaluronidase polypeptide contains at least one sugar moiety that is covalently attached to an asparagine residue of the hyaluronidase polypeptide; the hyaluronidase polypeptide is catalytically active; the hyaluronidase polypeptide is secreted; and the hyaluronidase polypeptide consists of a sequence of amino acids that has at least 98% amino acid sequence identity with the sequence of amino acids set forth as amino acid residues 36-483 of SEQ ID NO:1.

2. The method of claim 1, wherein the hyaluronidase polypeptide has at least 99% amino acid sequence identity with the sequence of amino acids set forth as amino acid residues 36-483 of SEQ ID NO:1.

3. A method for reducing intraocular pressure in the eye of a subject, comprising administering a composition comprising a hyaluronidase polypeptide to the eye, wherein: the hyaluronidase polypeptide contains at least one sugar moiety that is covalently attached to an asparagine residue of the hyaluronidase polypeptide; the hyaluronidase polypeptide is catalytically active; the hyaluronidase polypeptide is secreted; and the hyaluronidase polypeptide either: (i) consists of the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1; or (ii) has at least 95% sequence identity with the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1, wherein the amino acid sequence of the hyaluronidase polypeptide differs from the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO: 1 only by amino acid substitutions.

4. The method of claim 1, wherein the hyaluronidase polypeptide consists of residues 36-485 of SEQ ID NO:1.

5. The method of claim 1, wherein the hyaluronidase polypeptide is secreted when produced in CHO cells.

6. The method of claim 1, wherein the C-terminal residue of the hyaluronidase polypeptide in the composition is at a position corresponding to position 477, 478, 479, 480, 481, 482 or 483 of SEQ ID NO:1.

7. The method of claim 1, wherein the sequence of amino acid residues of the hyaluronidase polypeptide in the composition consists of residues 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1.

8. The method of claim 1, wherein the hyaluronidase polypeptide is chemically linked to a polymer.

9. The method of claim 3, wherein the hyaluronidase polypeptide is chemically linked to a polymer.

10. The method of claim 8, wherein the polymer is a polyethylene glycol (PEG) or a dextran.

11. The method of claim 10, wherein the polymer is a PEG.

12. The method of claim 9, wherein the polymer is a polyethylene glycol (PEG) or a dextran.

13. The method of claim 1, wherein the subject has glaucoma or has elevated intraocular pressure associated with cataracts or treatment of cataracts.

14. The method of claim 3, wherein the subject has glaucoma or has elevated intraocular pressure associated with cataracts or treatment of cataracts.

15. The method of claim 13, wherein the subject has been treated with viscoelastic substances.

16. The method of claim 13, wherein the subject has been treated with hyaluronic acid.

17. The method of claim 13, wherein the subject has open angle glaucoma.

18. The method of claim 1, wherein the subject has vitreous aggregates, vitreous hemorrhage, macular degeneration or diabetic retinopathy.

19. The method of claim 1, wherein the composition comprising the hyaluronidase polypeptide is co-administered with other enzymes that promote reshaping of the cornea by corrective contact lenses.

20. The method of claim 1, wherein the composition comprising the hyaluronidase polypeptide is administered intraocularly.

21. The method of claim 3, wherein the subject has vitreous aggregates, vitreous hemorrhage, macular degeneration or diabetic retinopathy.

22. The method of claim 3, wherein the composition comprising the hyaluronidase polypeptide is co-administered with other enzymes that promote reshaping of the cornea by corrective contact lenses.

23. The method of claim 3, wherein the composition comprising the hyaluronidase polypeptide is administered intraocularly.

24. The method of claim 3, wherein the hyaluronidase polypeptide consists of the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1.

Details for Patent 9,562,223

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 May 05, 2004 ⤷  Subscribe 2023-03-05
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 December 02, 2004 ⤷  Subscribe 2023-03-05
Amphastar Pharmaceuticals, Inc. AMPHADASE hyaluronidase Injection 021665 October 26, 2004 ⤷  Subscribe 2023-03-05
Akorn, Inc. HYDASE hyaluronidase Injection 021716 October 25, 2005 ⤷  Subscribe 2023-03-05
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.